The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.
Phase:
PHASE2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Eisai Inc. National Institute on Aging (NIA) National Institutes of Health (NIH)